Safety and efficacy of parenteral iron sucrose complex therapy in iron deficiency anemia in antenatal and postnatal women

Abstract

Background: Iron deficiency anaemia (IDA) is one of the common medical disorders in pregnancy in the developing world, which affect both the mother and the newborn and subsequent child and later adult. Aims & Objective: This study is undertaken to evaluate the safety and efficacy of parenteral iron sucrose complex therapy in iron deficiency anaemia in antenatal and postnatal women. Material and Methods: 110 consecutive pregnant women between 16-36 weeks of gestation and postnatal women, diagnosed as cases of Iron deficiency anaemia with Hb level 5-8 gm%, who were seen from May 2009 to April 2011 in our Hospital, were included in the study. All the patients received Iron Sucrose Complex in infusion form with the aim to correct the iron deficiency as well as to replenish the iron stores. The aim was to bring her Hb level to 10gm%. Result were analyzed in terms of the safety& efficacy, Results: Intravenous iron sucrose is effective in achieving target Hb of 10g/dl in 80% of patients. It shows that of IV iron sucrose significantly (P<0.001) increase Hb levels within 4 weeks. There were no major adverse reactions. All women stated that they found the treatment acceptable to them. Iron Sucrose Injection is relatively safe and well tolerated. Conclusion: Iron sucrose (intravenous) therapy is safe, more effective and well tolerated in the treatment of iron deficiency anaemia during pregnancy. Overall, iron sucrose appears to be a treatment of choice with no serious side effect indicated in the rapid correction of anaemia in pregnancy or restoring maternal iron stores, especially because the total dose can be administered over a shorter period of time. If used in time, this treatment will certainly help to reduce the risk of maternal and foetal complications as well as it also reduce the risk of blood transfusion during peripartum period.

Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India

“…[ 11 12 13 14 15 16 17 18 ] Nonetheless, our finding is well within the range of reported increase in Hb level of 1.6 g/dL to 3.6 g/dL. [ 11 12 13 14 15 16 17 18 ]…”

“…[ 14 ] In most of the published literature, an additional amount of 500 mg of iron was added to the calculated iron deficit for replenishing body iron reserve. [ 11 12 15 17 18 ] The maximum increase in Hb level (3.6 g/dL) was seen in a study that had added 1000 mg of iron for replenishment of iron store. [ 14 ] In our study, only 16.4% of moderately anemic pregnant women became nonanemic after receiving IVIS, and more than half (57.8%) of them remained in the same category even after receiving IVIS in recommended dose.…”

Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review

“…The prevalence of moderate or severe adverse reactions requiring treatment or discontinuation of IV iron was slightly higher in observational studies (13/1352; 9.6 per 1000 women; n = 20 studies) 12,13,19,20,22,23,32,33,40,41,44- [11][12][13][14][15][16]19,20,[22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][44][45][46][47][49][50][51] or FCM (1/276; 3.6 per 1000).…”

“…The majority of studies involved a comparison group of some kind including oral iron (n = 17; 36%), 11,14,16,19,24,26,27,29,31,32,34,35,37,39,50,56,57 IV iron (n = 4; 9%), 13 [14][15][16]18,20,24,26,28,31,[33][34][35][36][37][38][39]41,42,44,49,50,53 Only one study was identified that directly compared the administration of a full replacement dose of IV iron to a dose that was 300 mg less than the calculated full replacement dose. In comparing the two groups, administration of the full replacement dose was associated with a greater increase of 8 g/L 3-4 weeks after administration and 14 g/L at delivery.…”

Evaluation of intravenous iron sucrose therapy for management of moderate to severe anaemia in pregnancy

“…There were no major adverse reactions. 11 Neeru S et al rise in mean Hb was 2.06 gm%. 12 In Al-Memon AK et al rise in mean Hb was 2.5 gm% and rise in mean MCV was 10 ft. 13 In Kiran KV et al rise in mean Hb was 2.53 gm%.…”